The acquisition strengthens the company’s rare disease segment, and adds 2 durable commercial assets, Iluvien and Yutiq with ...

Oren Livnat has given his Buy rating due to a combination of factors including the recent acquisition of Alimera Sciences by ANI Pharmaceuticals, which is expected to be immediately accretive to the ...

ANI Pharmaceuticals (ANIP)  said it completed its planned acquisition of Alimera Sciences (NASDAQ:ALIM). Under the terms of ...

Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a ...

ANI Pharmaceuticals, Inc. ("ANI" or "the Company") (Nasdaq: ANIP) today provided an update on the status of the completion of its previously announced ...

Alimera Sciences (ALIM) saw its shares surge in the last session with trading volume being higher than average. The latest ...

Alimera Sciences Inc (ALIM) stock saw a modest uptick, ending the day at $5.53 which represents a slight increase of $0.34 or 6.55% from the prior close of $5.19. The stock opened at $5.53 and touched ...

ANI Pharmaceuticals acquiring Alimera Sciences for $5.50 per share with potential for $0.50 per share CVR, offering an ...

Alimera Sciences files lawsuit against ANI Pharmaceuticals over failed merger, causing stock to plummet 25% in premarket ...

Alimera Sciences, Inc. (ALIM), a biopharmaceutical company, announced on Tuesday that it has filed a lawsuit in the Delaware Court of ...

On June 24, ANI said it was buying Alimera Sciences for $5.50 per share in cash, in a deal that valued Alimera at $381 million. The offer represented a 75% premium to its closing share price of $3.15 ...